On Monday, Chemours Co (NYSE:CC)’s shares inclined 0.22% to $9.22.
The Chemours Company (CC), a global chemical company with leading market positions in titanium technologies, fluoroproducts and chemical solutions, declared financial results for the second quarter 2015. Chemours was a wholly-owned partner of DuPont during the period, and these results reflect a stand-alone basis of presentation.
Second quarter net sales were $1.5 billion, a decrease of 10 percent from $1.7 billion in the preceding-year quarter. Second quarter net loss was $18 million, or a pro forma net loss of $0.10 per diluted share, as compared to net income of $116 million in the second quarter 2014. Adjusted EBITDA was $127 million as compared to $235 million in the preceding year quarter. Profitability was reduced as a result of 11 percent lower-global- average local TiO2 prices, about $48 million from unfavorable currency movements and about $15 million from planned and unplanned plant outages. Lower year-over-year corporate and other operating costs partially offset these impacts.
The Chemours Company, a chemical company, provides titanium technologies, fluoroproducts, and chemical solutions. Its flagship products comprise brands, such as Teflon, Ti-Pure, Krytox Viton, Opteon, and Nafion. The company produces titanium dioxide, with Ti-Pure for coatings, plastics, laminates, and paper; and fluoroproducts, counting Teflon fluoropolymers, Krytox performance lubricants, Viton fluoroelastomers, and Opteon refrigerants.
Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE:YGE)’s shares dropped -12.00% to $0.792.
declared that it has received a notice on August 13, 2015 from the New York Stock Exchange (the “NYSE”) that the Company was not in compliance with the NYSE’s price criteria for continued listing standard because, as of August 12, 2015, the average closing price of the Company’s American Depositary Shares, or ADSs, was less than $1.00 per ADS over a successive 30 trading-day period.
Following Section 802.01C of the NYSE’s Listed Company Manual, the Company has six months (“the Cure Period”) following receipt of the notice to regain compliance with the minimum share price requirement. The Company can regain compliance during the Cure Period if the Company’s ADSs have a closing share price of at least $1.00 per ADS on the last trading day of any calendar month during the period and also have an average closing price of at least $1.00 per ADS over the 30 trading-day period ending on the last trading day of that month. The Company can also regain compliance if at the expiration of the six-month Cure Period, both a $1.00 or above closing price per ADS on the last trading day of the Cure Period and a $1.00 or above average closing price per ADS over the 30 trading-day period ending on the last trading day of the Cure Period are attained.
Yingli Green Energy Holding Company Limited, together with its auxiliaries, designs, develops, markets, manufactures, sells, and installs photovoltaic (PV) products in the People’s Republic of China and internationally. The company offers polysilicon ingots and blocks, polysilicon wafers, PV cells, PV modules, and integrated PV systems; and develops and operates solar projects.=
At the end of Monday’s trade, Amedica Corporation (NASDAQ:AMDA)‘s shares dipped -10.56% to $0.414.
Amedica Corporation (AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, declared that responses to the U.S. Food and Drug Administration (“FDA”) inquiries regarding the Company’s cervical composite silicon nitride interbody device were presented to the FDA on June 30, 2015. Additionally, the Company has received feedback from the FDA regarding its wear testing femoral head protocols.
Submission for 510(k) clearance of the Valeo C Interbody with CsC Osteo-Conductive Scaffolding (“Valeo C CsC”), which was presented in the first quarter of 2015, relates to the Company’s CASCADE clinical trial of its composite silicon nitride spinal interbody devices. Since submission, the Company received a list of questions from the FDA requesting additional information pertaining to the product’s clinical performance data, in addition to indications for use and device description. The Company has responded to the questions and now awaits clearance of the Class II medical device for commercial distribution or additional communication from the FDA.
Amedica Corporation, a commercial-stage biomaterial company, develops, manufactures, and sells a range of medical devices based on its silicon nitride technology platform in the United States, Europe, and South America. It offers Valeo silicon nitride interbody spinal fusion devices for use in the cervical and thoracolumbar areas of the spine; and a line of non-silicon nitride spinal fusion products.
LKQ Corporation (NASDAQ:LKQ), ended its Monday’s trading session with -2.65% loss, and closed at $28.69.
LKQ Corporation (LKQ) has again been named to the Fortune 500 list, Fortune magazine’s annual ranking of America’s largest companies by revenue. LKQ had 2014 total revenue of $6.7 billion. Fortune magazine ranked LKQ No. 403 on its list contrast to No. 490 last year.
LKQ Corporation, together with its auxiliaries, distributes replacement parts, components, and systems used in the repair and maintenance of vehicles in the United States, the United Kingdom, the Netherlands, Belgium, Northern France, Canada, Mexico, and Central America. The company operates in four segments: Wholesale North America, Wholesale Europe, Self Service, and Specialty. It distributes various products, counting aftermarket collision and mechanical products; recycled collision and mechanical products; and refurbished collision replacement products, such as wheels, bumper covers and lights, and remanufactured engines.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
